SANOFICONR

Sanofi Consumer Healthcare India Limited

Consumer healthcare products in allergy, pain management and VMS segments

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

sanofi.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-16

Stock price
₹3548.70
Market cap
8,173 Cr
Stock P/E
30.7
P/B
23.49
Dividend yield
1.6%
ROE (year to Dec 2025)
62.5%
ROCE (year to Dec 2025)
83.9%
Operating margin (year to Dec 2025)
33.8%
OCF / EBITDA (year to Dec 2025)
89.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Sanofi Consumer Healthcare India (SCHIL) sells self-care health brands such as Allegra and Avil for allergy and Combiflam for pain, to consumers in India and through exports.

Company snapshot

48thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Net margin of 27.3% — the business keeps a healthy share of every rupee it earns.
4 more signals from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales164 Cr160 Cr171 Cr173 Cr221 Cr234 Cr251 Cr229 Cr236 Cr
Operating expenses (approx.)101 Cr97 Cr109 Cr109 Cr151 Cr149 Cr161 Cr140 Cr146 Cr
EBITDA64 Cr63 Cr62 Cr64 Cr70 Cr85 Cr90 Cr89 Cr89 Cr
OPM %38.7%39.5%36.4%37.1%31.8%36.3%35.8%38.7%37.9%
Other income0.80 Cr4 Cr5 Cr5 Cr6 Cr3 Cr5 Cr6 Cr6 Cr
Interest0.10 Cr3 Cr0.40 Cr0.40 Cr0.50 Cr0.60 Cr0.50 Cr0.50 Cr0.40 Cr
Depreciation1 Cr2 Cr1 Cr2 Cr3 Cr3 Cr3 Cr3 Cr3 Cr
Profit before tax39 Cr61 Cr63 Cr67 Cr79 Cr84 Cr91 Cr91 Cr92 Cr
Tax %25.4%26.5%29.5%25.1%23.1%25.2%26.5%25.2%25.1%
Net profit29 Cr45 Cr44 Cr50 Cr61 Cr63 Cr67 Cr68 Cr69 Cr
EPS (₹)₹12.58₹19.54₹19.25₹21.69₹26.36₹27.31₹28.87₹29.44₹29.87

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricDec 2024Dec 2025TTM
Sales725 Cr878 CrSign in free for the trailing twelve months
Operating expenses (approx.)454 Cr569 CrSign in free for the trailing twelve months
EBITDA271 Cr309 CrSign in free for the trailing twelve months
OPM %37.3%35.2%Sign in free for the trailing twelve months
Other income13 Cr18 CrSign in free for the trailing twelve months
Interest4 Cr2 CrSign in free for the trailing twelve months
Depreciation5 Cr12 CrSign in free for the trailing twelve months
Profit before tax247 Cr320 CrSign in free for the trailing twelve months
Tax %26.7%25.0%Sign in free for the trailing twelve months
Net profit181 Cr240 CrSign in free for the trailing twelve months
EPS (₹)₹78.59₹104.27Sign in free for the trailing twelve months
Dividend payout %0.0%52.8%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricDec 2024Dec 2025
Equity capital23 Cr23 Cr
Reserves250 Cr361 Cr
Borrowings——
Other liabilities158 Cr163 Cr
Total liabilities431 Cr547 Cr
Fixed assets (net)27 Cr35 Cr
CWIP0.70 Cr0.0070 Cr
Investments0 Cr0 Cr
Loans & advances0.60 Cr0.10 Cr
Inventories41 Cr62 Cr
Trade receivables14 Cr30 Cr
Cash & bank327 Cr375 Cr
Other assets21 Cr45 Cr
Total assets431 Cr547 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricDec 2024Dec 2025
Cash from operating activity439 Cr277 Cr
Cash from investing2 Cr-8 Cr
Cash from financing-116 Cr-222 Cr
Net cash flow325 Cr48 Cr
Free cash flow (OCF − Capex)429 Cr270 Cr

Ratios

MetricDec 2024Dec 2025
ROCE %91.8%83.9%
ROE %66.3%62.5%
Debtor days712
Inventory days117140
Days payable201180
Cash conversion cycle-77-28
OCF / EBITDA %162.2%89.8%
Debt / equity——
Current ratio3.003.85
Net debt / EBITDA-1.21-1.21